Galbanic acid |
Ferula assafoetida
|
Decreases molecular angiogenesis pathways including VEGF, MAPK, JNK, and AKT |
5, 10, 20, 40 µM for in vitro study and 0.1, 1 mg/Kg for Lewis lung cancer (LLC) mouse model, intraperitoneally (i.p.) injected once daily for 18 days |
[126] |
Umbelliprenin |
Ferula species |
Reduces and blocks angiogenesis marker activity including Ki-67, CD31, VEGF, MMP2, MMP9, and E-cadherin |
3, 6.25, 12.5, 25, 50, 100, and 200 µg/mL |
[127] |
Murrangatin |
Micromelum falcatum
|
Inhibition of phosphoinositol 3-kinase (PI3K)/AKT activity as angiogenic inducer |
10, 50, 100 µM |
[125] |
Imperatorin |
Angelica dahurica and Angelica archangelica
|
Blocks the expression of nuclear factor (NF-κB) target genes, such as MMP-9, VEGF, IL-6 that are induced by TNF-α |
50, 100, 150 µM |
[117] |
Auraptene |
Citrus sinensis
|
Inhibition of angiogenesis via suppression of MMP-2,9 |
12.5, 25, 50, 100 µM |
[128] |
Esculetin |
Artemisia scoparia
|
Inhibition of angiogenesis via decreasing MMP expression and blocking phosphorylation of VEGFR-2, ERK1/2, Akt, and endothelial nitric oxide synthase (eNOS) induced by VEGF (20 ng/mL) |
12.5, 25, 50 µg/ml |
[31] |
Osthol |
Cnidium monnieri
|
Reduction of microvessel density (MVD) with blocked expression of VEGF and NF-κB |
61, 122, and 244 mg/kg, i.p, once daily for two weeks in a mouse model of hepatocellular carcinoma (HCC) |
[129] |
Conferone |
Ferula szwitsiana
|
Reduction of the production of the pro-angiogenic factors VEGF, Angiopoietin-1, and Angiopoietin -2 |
20 µM |
[123] |
Daphnetin |
Changbai daphne
|
Inhibition of the expression of proteins involved in angiogenesis induced by VEGF such as MAPK, VEGFR2, ERK1/2, AKT, focal adhesion kinase (FAK), cSrc, and MMP and inhibition of NF-κB induced by TNF-α |
37.5, 75, 150 µM |
[124] |
Scopolin |
Erycibe obtusifolia Benth |
Decreases VEGF, FGF-2 and IL-6 expressions |
25, 50, 100 mg/kg, i.p, once daily for 10 days |
[130] |